1. Home
  2. CTMX

CTMX

CytomX Therapeutics Inc.

Logo CytomX Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 11:32am EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Founded: 2008 Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 113.1M IPO Year: 2015
Target Price: $3.13 AVG Volume (30 days): 924.0K
Analyst Decision: Hold Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.01 EPS Growth: N/A
52 Week Low/High: $1.04 - $2.85 Next Earning Date: 05-07-2024
Revenue: $101,214,000 Revenue Growth: 90.38%
Revenue Growth (this year): -8.75% Revenue Growth (next year): -14.43%

Share on Social Networks: